Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Johns Hopkins Medicine Treats First Commercial TULSA-PRO(TM) Case

By The Northwire Desk — AI Analysis Jan 06, 2026 · 07:45 PRN · 10.65 PROFOUND MEDICAL CORP.
PRN · Price

Executive Summary

  • Profound Medical announced that The Johns Hopkins Hospital treated its first non‑clinical‑trial prostate cancer patient using the TULSA‑PRO® system, marking the official launch of the technology at a leading academic medical center.
  • The treatment was performed in Johns Hopkins Medicine’s newly opened interventional MRI (iMRI) suite, highlighting the integration of real‑time therapeutic MRI platforms.
  • CEO Arun Menawat emphasized the significance of this partnership given Johns Hopkins’ early involvement in TULSA‑PRO’s pivotal trials and its role in post‑market studies.

Key Details

  • Milestone: First non‑clinical‑trial prostate cancer patient treated with TULSA‑PRO® at Johns Hopkins Hospital.
  • Location: New interventional MRI (iMRI) suite at Johns Hopkins Medicine, enabling real‑time MR‑guided procedures.
  • Technology Overview:
  • AI‑powered, MRI‑guided, incision‑free therapy delivering robotically controlled directional ultrasound via the urethra.
  • Real‑time MR thermography provides continuous temperature monitoring and autonomous adjustment (target 55‑57 °C).
  • Clinical benefits include no procedural blood loss, no overnight hospital stay, rapid recovery, and reduced risk of urinary incontinence or erectile dysfunction.
  • Clinical Context: TULSA‑PRO is FDA 510(k) cleared, CE marked, and Health Canada approved for treatment of prostate cancer across risk levels and benign prostatic hyperplasia (BPH).
  • CEO Quote: “We are thrilled to see Johns Hopkins Medicine now offer TULSA‑PRO to their patients… the implementation of TULSA‑PRO in a newly built interventional MR suite specifically designed for surgical procedures that benefit from the precision of real‑time MRI… is a growing movement.” – Arun Menawat, CEO & Chairman.
  • Additional Portfolio: Profound also commercializes Sonalleve®, a CE‑marked platform for uterine fibroids, adenomyosis, bone metastasis pain palliation, desmoid tumors, and osteoid osteoma; it holds approvals in China and a Humanitarian Device Exemption in the U.S.

Notable Quotes

  • “The implementation of TULSA‑PRO in a newly built interventional MR suite… is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend.” – Arun Menawat, CEO and Chairman, Profound Medical.
Read the original news release →

More from PROFOUND MEDICAL CORP.

May 15, 2026 · 06:30

Profound Medical Corp.

Other May 14, 2026 · 07:00

TULSA-PRO's Conference Glow Hides a Long Road to Profitability

Other May 07, 2026 · 16:05

Humana coverage and surging procedure volumes push TULSA-PRO toward standard of care, but path to profitability still requires execution.

Earnings Mar 27, 2026 · 15:15

Profound talks up Tulsa procedure milestone in Texas

Production / Operations Mar 27, 2026 · 07:45

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

Other Mar 13, 2026 · 10:30

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Other